8-K: Aquestive Therapeutics Highlights Anaphylm Data at Upcoming AAAAI Annual Meeting

Aquestive Therapeutics will present new findings on its Anaphylm epinephrine sublingual film at the 2025 AAAAI Annual Meeting, showcasing its stability, potency, and effectiveness in treating severe allergic reactions.

Summary

• Aquestive Therapeutics is set to present data on Anaphylm, its epinephrine sublingual film, at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting.
• The presentations will highlight Anaphylm's consistent stability and potency under various conditions, including extreme temperatures and water submersion.
• New findings demonstrate consistent epinephrine absorption with Anaphylm, without impacting safety or pharmacodynamic parameters, even with oral swelling.
• In the OASIS study, Anaphylm matched or exceeded intramuscular epinephrine in key pharmacokinetic parameters.
• The median symptom resolution time with Anaphylm was 12 minutes, compared to 74 minutes without treatment, and the mean angioedema symptom resolution time was within 5 minutes.

Sentiment

Score: 8

Explanation: The document presents positive clinical data for Anaphylm, highlighting its potential as a convenient and effective treatment for anaphylaxis. The management's comments are optimistic, and the overall tone suggests confidence in the product's future.

Positives

• Anaphylm demonstrates consistent stability and potency under extreme conditions, suggesting it is reliable for real-world use.
• The drug's performance is not affected by oral swelling, which is a common symptom of allergic reactions.
• Clinical data suggests Anaphylm is as effective as intramuscular epinephrine in key pharmacokinetic parameters.
• Anaphylm shows rapid symptom resolution, with a median time of 12 minutes compared to 74 minutes without treatment.

Risks

• The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• Risks include delays or changes to the timing, cost and success of product development activities and clinical trials.
• There is a risk of delays in the regulatory approval process through the FDA, including the filing of the respective NDAs.
• The company faces the risk of not generating sufficient clinical data for approval of product candidates.
• There is a risk of the company's ability to address the FDA's comments on the company's clinical trials and other concerns identified in the FDA Type C meeting minutes for Anaphylm, including the risk that the FDA may require additional clinical studies for approval of Anaphylm.

Future Outlook

The company anticipates the advancement and FDA approval of Anaphylm and AQST-108, with potential benefits for patients and various market opportunities.

Management Comments

• Daniel Barber, Chief Executive Officer of Aquestive, stated that the latest results reinforce the strength of the clinical data and the potential of Anaphylm as a reliable, portable, and effective treatment for anaphylaxis.
• Anaphylm was designed to offer patients a more accessible option for emergency epinephrine administration, without the need for an injection or device, if approved by the FDA.

Industry Context

The development of Anaphylm addresses the need for more accessible and convenient epinephrine delivery methods, competing with existing injectable epinephrine products like EpiPen and Auvi-Q. The sublingual film format offers a potential advantage in ease of use and portability.

Comparison to Industry Standards

• The study compares Anaphylm to intramuscular epinephrine, the current standard of care for anaphylaxis.
• The results suggest that Anaphylm matches or exceeds IM epinephrine in key pharmacokinetic parameters, indicating comparable efficacy.
• Competitors in the anaphylaxis treatment market include Mylan (EpiPen), Kaleo (Auvi-Q), and Teva Pharmaceuticals, all offering injectable epinephrine products.
• The median symptom resolution time of 12 minutes with Anaphylm is a key metric for comparison against these existing treatments.

Stakeholder Impact

• Shareholders may benefit from the potential FDA approval and commercialization of Anaphylm.
• Patients with severe allergies could gain a more accessible and convenient treatment option.
• The company's employees may see increased job security and growth opportunities.
• Positive results could strengthen Aquestive's relationships with pharmaceutical partners.

Next Steps

• Aquestive will present multiple posters at the AAAAI Annual Meeting from February 28 March 3, 2025.
• The company is advancing Anaphylm through clinical development and seeking FDA approval.
• Aquestive plans to file an NDA for Anaphylm with the FDA and launch the product if approved.

Key Dates

Keywords

Anaphylm, Aquestive Therapeutics, Epinephrine Sublingual Film, Anaphylaxis, AAAAI Annual Meeting, Allergic Reaction, AQST, PharmFilm